Abstract
Introduction. The need for cardiac care to patients with cancer, given the prevalence of diseases, in recent
years, is still growing. On the one hand, the presence of competing coronary heart disease (CHD) in patients
with malignant neoplasms in some cases, is a contraindication for surgical treatment, and also can significantly
limit the amount of surgeries for cancer pathology. On the other hand, coronary heart disease in
patients with cancer may increase the frequency of postoperative complications, hospital mortality, and
reduce long survival following radical surgery on cancer. Myocardial revascularization performed, the first
stage in patients with hemodynamically significant stenosis of the coronary arteries, is the primary method
of treatment to prevent the development of cardiovascular complications during and after the second stage
of surgical treatment. Long-term results help to determine if surgical treatment is justified.
Material and methods. A total of 205 patients with cancer history who underwent coronary artery bypass
surgery on a beating heart was performed (for OPCAB technique). The control group included 205 patients
who did not have cancer. Patients were matched according to the parameters age, sex, disease and on accompanying
operation type. Patients were retrospectively χ2 test analysis was performed by the method of
Kaplan–Meier and Cox regression.
Results. During follow-up was 95.8% of patients tracked. Univariate analysis showed that the 5- and 10-year
survival was higher in patients without a history of cancer (0.91 ± 0.02 vs. 0.72 ± 0.03 and 0.73 ± 0.04 vs.
0.40 ± 0.05; p<0.0001). At shorter intervals, all-cause mortality and mortality due to cancer was significantly
higher (p<0.0001). Multivariate analysis identified four independent variables: a malignant tumor in history
(p<0.001), COPD (p=0.003), age (p=0.001) and impaired left ventricular function (p=0.035)
Conclusion. A history of malignancy is the most important prognostic factor for coronary artery bypass
surgery (CABG) surgery, however, the operation is still justified. Fatal tumor progression observed in the case
between the detection of a malignant tumor and CABG surgery took a bit of time. Other adverse factors
include decreased left ventricular function, COPD and old age.
References
- Demographic results 2012 (part II). Demoscope weekly: electronic version of the Bulletinn “Population and society” Available at: http://demoscope.ru/weekly/2013/0543/barom 02.php (in Russian).
- Dombrovskiy M.M. Endovascular treatment of ischemic heart disease in patients with cancer. Byulleten' Nauchnogo Tsentra Serdechno-Sosudistoy Khirurgii imeni A.N. Bakuleva RAMN. 2014; 15 (1): 14–23 (in Russian).
- Kuper H., Bofetta P., Adami H.O. Tobacco use and cancer causation: association by tumor type. J. Intern. Med. 2002; 252: 204–6.
- Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002; 62 (Suppl 2): 1–19.
- Thomas L.A. Sending unhealthy environments up in smoke. Mich. Health. Hosp. 2002; 38: 20–1. 6. Danton M.H.D., Anikin V.A., McManus K.G., McGuigan J.A., Campalani G. Simultaneous cardiac surgery with pulmonary resection: presentation of series and review of literature. Eur. J. Cardiothorac. Surg. 1998; 13: 667–72.
- Al-Attar N., Salvi S., Sebbag U., Nataf P. Combined left pneumonectomy and off-pump coronary artery bypass through left thoracotomy. Eur. J. Cardiothorac. Surg. 2001; 19: 226–8.
- Hensens A.G., Zeebregts C.J., Liem T.H., Gehlmann H., Lacquet L.H. Concomitant coronary artery revascularisation and right pneumonectomy without cardiopulmonary bypass. J. Cardiovasc. Surg. 1999; 40: 161–3.
- Rubens F.D., O'Brien E., Shamji F., O'Neil J., Odell P.F. Sternothoractomy for combined coronary artery bypass grafting and left upper lobectomy in a patient with low-lying tracheostoma. Can. J. Surg. 1999; 42: 143–4.
- Jones J.M., Melua A.A., Anikin V., Campalini G. Simultaneous transhiatal esophagectomy and coronary artery bypass grafting without cardiopulmonary bypass. Dis. Esophagus. 1999; 12: 312–13.
- Yokoyama T., Derrick M.J., Lee A.W. Cardiac operation with associated pulmonary resection. J. Thorac. Cardiovasc. Surg. 1993; 105: 912–17.
- La Francesca S., Frazier O.H., Radovancevic B., De Caro L.F., Reul G.J., Cooley D.A. Concomitant cardiac and pulmonary operations for lung cancer. Texas Heart Inst. J. 1995; 22 (4): 296–300.
- Mariani M.A., van Boven W.J., Duurkens V.А., Ernst S.M., van Swieten H.A. Combined off-pump coronary surgery and right lung resections through midline sternotomy. Ann. Thorac. Surg. 2001; 71 (4): 1343–7.
- Miller D.L., Orszulak T.A., Pairolero P.C., Trastek V.F., Schaff H.F. Combined operation for lung cancer and cardiac disease. Ann. Thorac. Surg. 1994; 58 (4): 989–95.
- Ochi M., Yamada K., Fujii M., Ohkubo N., Ogasawara H., Tanaka S. Role of off-pump coronary artery bypass grafting in patients with malignant neoplastic disease. Jap. Circ. J. 2000; 64 (1): 13–7.
- Takahashi T., Nakano S., Shimazaki Y., Kaneko M., Nakahara K., Miyata M. et al. Concomitant coronary bypass grafting and curative surgery for cancer. Surg. Today. 1995; 25 (2): 131–5.
- Watanabe S., Shimokawa S., Sakasegawa K., Yamaoka A., Yamamoto H., Shiota K. et al. Simultaneous operation for lung tumor and cardiovascular disease. Kyobu Geka. 2000; 53 (5): 353–7
- Zöller B., Ji J., Sundquist J., Sundquist K. Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur. J. Cancer. 2012; 48 (12): 1875–83
- Mistiaen W.P., Van Cauwelaert P., Muylaert P. et al. Determinants of survival after aortic valve replacement as treatment for symptomatic aortic valve disease in the elderly. J. Heart. Valve Dis. 2001; 10: 354–60.
- Davydov M.I., Shestopalova I.I., Gerasimov S.S., Komarova L.E. Possibilities of curing cancer patients with thoraco-abdominal localization of the tumor and comorbid coronary artery disease. Byulleten’ Rossiyskogo Oncologicheskogo Nauchnogo Tsentra imeni N.N. Blokhina. 2009; 20 (3): 36–41 (in Russian).
- Tipisev D.A., Gorobets E.S., Sviridova S.P., Kashiya Sh.R., Makhlay A.V. About the possibility of surgical treatment of cancer patient with a high risk of perioperative cardiovascular complications. VI Russian oncological conference. The materials of congresses and conferences. The Internet portal of the Russian Society of Clinical Oncology in the project Oncology.ru (in Russian).
- Markewitz A., Lante W., Franke A., Marohl K., Kuhlmann W.D., Weinhold C. Alterations of cellmediated immunity following cardiac operations: clinical implications and open questions. Shock. 2001; 16 (Suppl 1): 10–5.
- Sablotski A., Welters I., Lehmann N. et al. Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary artery bypass grafing. Eur. J. Cardiothorac. Surg. 1997; 11: 763–8.
- Markewitz A., Faist E., Lang S., Hultner L., Weinhold C., Reichart B. An imbalance in T-helper cells subsets alters immune response after cardiac surgery. Eur. J. Cardiothorac. Surg. 1996; 10: 61–7.
- Payen D., Faivre V., Lukaszewicz A.C., Losser M.R. Assessment of immunological status in the critically ill. Minerva Anestesiol. 2000; 66: 757–63.
- O'Byrne K.J., Dalgleish A.G., Browning M.J., Steward W.P., Harris A.L. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer. 2000; 36: 151–69.
- Nanni P., Nicoletti G., De Giovanni C. et al. Combined allogeneic tumour cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/leu trangene mice. J. Exp. Med. 2001; 194: 1195–205.
- Lamm D.L., Riggs D.R. The potential application of Allium Sativum for the treatment of bladder cancer. Urol. Clin. North. Am. 2000; 27: 157–62.
- Mise-Omata S., Sugiura T., Higashi K., Yamashita U. Reduces T cell response in carcinogen-sensitive Donryu rats compared with carcinogen-resistant DHR rats. Jap. J. Cancer. Res. 1999; 90: 1277–84.
- Enwonwu C.O., Meeks V.I. Bionutrition and oral cancer in humans. Crit. Rev. Oral. Biol. Med. 1995; 6: 5–17.
